Xeris Biopharma Holdings, Inc. XERS Proceeds From Issuance Of Warrants
Proceeds From Issuance Of Warrants at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfWarrants.
The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xeris Biopharma Holdings, Inc.'s proceeds from issuance of warrants.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xeris Biopharma Holdings, Inc.'s proceeds from issuance of warrants?
- Xeris Biopharma Holdings, Inc. (XERS) reported proceeds from issuance of warrants of $7.33M in Q1 2026.
- What does proceeds from issuance of warrants mean?
- This captures the cash proceeds received by the company from the issuance of warrants, which grant holders the right to purchase shares at a specified price. It serves as a source of equity financing that can strengthen the balance sheet. Investors monitor this to assess potential future dilution and the company's ability to raise capital through derivative instruments.